Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Celgene (CELG) to Post Q1 Earnings: What's in the Cards?

Celgene Corporation (CELG) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

    What's in Store for Agenus (AGEN) this Earnings Season?

    Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.

      What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?

      GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.

        Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?

        We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.

          Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?

          Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.

            Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?

            Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.

              Arpita Dutt headshot

              Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback

              Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.

                Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion

                Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.

                  KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day

                  KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day

                    Kevin Cook headshot

                    Bear of the Day: Gilead Sciences (GILD)

                    Could a transformational M&A deal reverse the 18-month slide in sales and profits?

                      Arpita Dutt headshot

                      Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug

                      Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.

                        Gilead (GILD) Up 4.3% Since Earnings Report: Can It Continue?

                        Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Galapagos Initiates 3 Phase II Studies for Filgotinib

                          Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.

                            New Strong Sell Stocks for March 31st

                            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                              Arpita Dutt headshot

                              Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study

                              Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.

                                Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

                                Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

                                  Arpita Dutt headshot

                                  Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

                                  Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

                                    Mylan Receives Tentative Approval from FDA for HIV Therapy

                                    Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).

                                      Kevin Cook headshot

                                      Biotech Bull Making a Comeback

                                      A triple-bottom at $240 was bolstered by the headline capitulation of an infamous Valeant investor

                                        Arpita Dutt headshot

                                        Why Biotech Stock Gilead (GILD) Could Be a Value Trap

                                        Gilead's (GILD) valuation looks compelling but is the company really poised for

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

                                          The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

                                            Forget Gilead, Buy These Small-Cap Biotech Stocks Instead

                                            At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.

                                              Sarepta's DMD Drug Launch Slow; What's in Store for 2017?

                                              We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal

                                                Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.

                                                  Arpita Dutt headshot

                                                  Is This the Right Time to Invest in Biotech Stocks?

                                                  The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?